In vivo targeting of human DC-SIGN drastically enhances CD8+ T-cell-mediated protective immunity

European Journal of Immunology

Volumn 43, Issue 10, 2013, Pages 2543-2553

  Hesse, Christina ^a   Ginter, Wiebke ^a   Förg, Theresa ^a   Mayer, Christian T ^a   Baru, Abdul Mannan ^a   Arnold Schrauf, Catharina ^a   Unger, Wendy W J ^b   Kalay, Hakan ^b   van Kooyk, Yvette ^b   Berod, Luciana ^a   Sparwasser, Tim ^a  

^a INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Crosspresentation; DC SIGN; Dendritic cells; Listeria; Vaccine

Indexed keywords

CD209 ANTIBODY OVALBUMIN; CD209 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL CLEARANCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; DRUG TARGETING; IMMUNE RESPONSE; INFECTION PREVENTION; LISTERIA MONOCYTOGENES; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

CROSSPRESENTATION; DC-SIGN; DENDRITIC CELLS; LISTERIA; VACCINE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11C; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL ADHESION MOLECULES; DENDRITIC CELLS; HUMANS; IMMUNITY, ACTIVE; IMMUNITY, CELLULAR; IMMUNOMODULATION; LECTINS, C-TYPE; LISTERIA MONOCYTOGENES; MICE; MICE, TRANSGENIC; OVALBUMIN; PROMOTER REGIONS, GENETIC; RECEPTORS, CELL SURFACE; TRANSGENES; VACCINATION;

EID: 84885758381     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201343429     Document Type: Article

References (46)

1. Tacken, P. J., de Vries, I. J., Torensma, R. and Figdor, C. G., Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 2007. 7: 790-802.
2. Bonifaz, L. C., Bonnyay, D. P., Charalambous, A., Darguste, D. I., Fujii, S., Soares, H., Brimnes, M. K. et al., In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 2004. 199: 815-824.
3. Unger, W. W., van Beelen, A. J., Bruijns, S. C., Joshi, M., Fehres, C. M., van Bloois, L., Verstege, M. I. et al., Glycan-modified liposomes boost CD4(+) and CD8(+) T-cell responses by targeting DC-SIGN on dendritic cells. J. Control Release 2012. 160: 88-95.
4. Singh, S. K., Stephani, J., Schaefer, M., Kalay, H., Garcia-Vallejo, J. J., den Haan, J., Saeland, E. et al., Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation. Mol. Immunol. 2009. 47: 164-174.
5. Bonifaz, L., Bonnyay, D., Mahnke, K., Rivera, M., Nussenzweig, M. C. and Steinman, R. M., Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J. Exp. Med. 2002. 196: 1627-1638.
6. Idoyaga, J., Lubkin, A., Fiorese, C., Lahoud, M. H., Caminschi, I., Huang, Y., Rodriguez, A. et al., Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc. Natl. Acad. Sci. USA 2011. 108: 2384-2389.
7. Keler, T., Ramakrishna, V. and Fanger, M. W., Mannose receptor-targeted vaccines. Expert. Opin. Biol. Ther. 2004. 4: 1953-1962.
8. Caminschi, I., Proietto, A. I., Ahmet, F., Kitsoulis, S., Shin Teh, J., Lo, J. C., Rizzitelli, A. et al., The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood 2008. 112: 3264-3273.
9. Witmer-Pack, M. D., Swiggard, W. J., Mirza, A., Inaba, K. and Steinman, R. M., Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLDC-145. II. Expression in situ in lymphoid and nonlymphoid tissues. Cell Immunol. 1995. 163: 157-162.
10. Dudziak, D., Kamphorst, A. O., Heidkamp, G. F., Buchholz, V. R., Trumpfheller, C., Yamazaki, S., Cheong, C. et al., Differential antigen processing by dendritic cell subsets in vivo. Science 2007. 315: 107-111.
11. Hawiger, D., Inaba, K., Dorsett, Y., Guo, M., Mahnke, K., Rivera, M., Ravetch, J. V. et al., Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 2001. 194: 769-779.
12. Trumpfheller, C., Finke, J. S., Lopez, C. B., Moran, T. M., Moltedo, B., Soares, H., Huang, Y. et al., Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J. Exp. Med. 2006. 203: 607-617.
13. Bozzacco, L., Trumpfheller, C., Siegal, F. P., Mehandru, S., Markowitz, M., Carrington, M., Nussenzweig, M. C. et al., DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc. Natl. Acad. Sci. USA 2007. 104: 1289-1294.
14. Kato, M., McDonald, K. J., Khan, S., Ross, I. L., Vuckovic, S., Chen, K., Munster, D. et al., Expression of human DEC-205 (CD205) multilectin receptor on leukocytes. Int. Immunol. 2006. 18: 857-869.
15. Geijtenbeek, T. B., Torensma, R., van Vliet, S. J., van Duijnhoven, G. C., Adema, G. J., van Kooyk, Y. and Figdor, C. G., Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000. 100: 575-585.
16. Soilleux, E. J., Morris, L. S., Leslie, G., Chehimi, J., Luo, Q., Levroney, E., Trowsdale, J. et al., Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. J. Leukoc. Biol. 2002. 71: 445-457.
17. van Kooyk, Y. and Geijtenbeek, T. B., DC-SIGN: escape mechanism for pathogens. Nat. Rev. Immunol. 2003. 3: 697-709.
18. Engering, A., Van Vliet, S. J., Geijtenbeek, T. B. and Van Kooyk, Y., Subset of DC-SIGN(+) dendritic cells in human blood transmits HIV-1 to T lymphocytes. Blood 2002. 100: 1780-1786.
19. Tacken, P. J., de Vries, I. J., Gijzen, K., Joosten, B., Wu, D., Rother, R. P., Faas, S. J. et al., Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 2005. 106: 1278-1285.
20. Joshi, M. D., Unger, W. W., van Beelen, A. J., Bruijns, S. C., Litjens, M., van Bloois, L., Kalay, H. et al., DC-SIGN mediated antigen-targeting using glycan-modified liposomes: formulation considerations. Int. J. Pharm. 2011. 416: 426-432.
21. Kretz-Rommel, A., Qin, F., Dakappagari, N., Torensma, R., Faas, S., Wu, D. and Bowdish, K. S., In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models. J. Immunother. 2007. 30: 715-726.
22. Lara-Tejero, M. and Pamer, E. G., T cell responses to Listeria monocytogenes. Curr. Opin. Microbiol. 2004. 7: 45-50.
23. Schaefer, M., Reiling, N., Fessler, C., Stephani, J., Taniuchi, I., Hatam, F., Yildirim, A. O. et al., Decreased pathology and prolonged survival of human DC-SIGN transgenic mice during mycobacterial infection. J. Immunol. 2008. 180: 6836-6845.
24. Tacken, P. J., Ginter, W., Berod, L., Cruz, L. J., Joosten, B., Sparwasser, T., Figdor, C. G. and Cambi, A., Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation. Blood 2011. 118: 4111-4119.
25. Hermans, I. F., Silk, J. D., Yang, J., Palmowski, M. J., Gileadi, U., McCarthy, C., Salio, M. et al., The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. J. Immunol. Methods 2004. 285: 25-40.
26. Spellberg, B. J., Ibrahim, A. S., Avanesian, V., Fu, Y., Myers, C., Phan, Q. T., Filler, S. G. et al., Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J. Infect. Dis. 2006. 194: 256-260.
27. Seder, R. A. and Hill, A. V., Vaccines against intracellular infections requiring cellular immunity. Nature 2000. 406: 793-798.
28. Geijtenbeek, T. B., Engering, A. and Van Kooyk, Y., DC-SIGN, a C-type lectin on dendritic cells that unveils many aspects of dendritic cell biology. J. Leukoc. Biol. 2002. 71: 921-931.
29. Figdor, C. G., van Kooyk, Y. and Adema, G. J., C-type lectin receptors on dendritic cells and Langerhans cells. Nat. Rev. Immunol. 2002. 2: 77-84.
30. Caminschi, I., Corbett, A. J., Zahra, C., Lahoud, M., Lucas, K. M., Sofi, M., Vremec, D. et al., Functional comparison of mouse CIRE/mouse DC-SIGN and human DC-SIGN. Int. Immunol. 2006. 18: 741-753.
31. Baribaud, F., Pohlmann, S., Sparwasser, T., Kimata, M. T., Choi, Y. K., Haggarty, B. S., Ahmad, N. et al., Functional and antigenic characterization of human, rhesus macaque, pigtailed macaque, and murine DC-SIGN. J. Virol. 2001. 75: 10281-10289.
32. Engering, A., Geijtenbeek, T. B., van Vliet, S. J., Wijers, M., van Liempt, E., Demaurex, N., Lanzavecchia, A. et al., The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. J. Immunol. 2002. 168: 2118-2126.
33. Stern, J. N., Keskin, D. B., Kato, Z., Waldner, H., Schallenberg, S., Anderson, A., von Boehmer, H. et al., Promoting tolerance to proteolipid protein-induced experimental autoimmune encephalomyelitis through targeting dendritic cells. Proc. Natl. Acad. Sci. USA 2010. 107: 17280-17285.
34. Stylianou, E., Pepponi, I., van Dolleweerd, C. J., Paul, M. J., Ma, J. K. and Reljic, R., Exploring the vaccine potential of DEC-205 targeting in Mycobacterium tuberculosis infection in mice. Vaccine 2011. 29: 2279-2286.
35. Mahnke, K., Qian, Y., Fondel, S., Brueck, J., Becker, C. and Enk, A. H., Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. Cancer Res. 2005. 65: 7007-7012.
36. Castro, F. V., Tutt, A. L., White, A. L., Teeling, J. L., James, S., French, R. R. and Glennie, M. J., CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses. Eur. J. Immunol. 2008. 38: 2263-2273.
37. Loschko, J., Heink, S., Hackl, D., Dudziak, D., Reindl, W., Korn, T. and Krug, A. B., Antigen targeting to plasmacytoid dendritic cells via Siglec-H inhibits Th cell-dependent autoimmunity. J. Immunol. 2011. 187: 6346-6356.
38. Vyas, J. M., Van der Veen, A. G. and Ploegh, H. L., The known unknowns of antigen processing and presentation. Nat. Rev. Immunol. 2008. 8: 607-618.
39. Flinsenberg, T. W., Compeer, E. B., Boelens, J. J. and Boes, M., Antigen cross-presentation: extending recent laboratory findings to therapeutic intervention. Clin. Exp. Immunol. 2011. 165: 8-18.
40. Bachem, A., Hartung, E., Guttler, S., Mora, A., Zhou, X., Hegemann, A., Plantinga, M. et al., Expression of XCR1 characterizes the batf3-dependent lineage of dendritic cells capable of antigen cross-presentation. Front Immunol. 2012. 3: 214.
41. Moser, M. and Murphy, K. M., Dendritic cell regulation of TH1-TH2 development. Nat. Immunol. 2000. 1: 199-205.
42. Corbett, A. J., Caminschi, I., McKenzie, B. S., Brady, J. L., Wright, M. D., Mottram, P. L., Hogarth, P. M. et al., Antigen delivery via two molecules on the CD8-dendritic cell subset induces humoral immunity in the absence of conventional "danger". Eur. J. Immunol. 2005. 35: 2815-2825.
43. Wang, B., Kuroiwa, J. M., He, L. Z., Charalambous, A., Keler, T. and Steinman, R. M., The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells. Ann. NY Acad. Sci. 2009. 1174: 6-17.
44. Lutz, M. B., Kukutsch, N., Ogilvie, A. L., Rossner, S., Koch, F., Romani, N. and Schuler, G., An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 1999. 223: 77-92.
45. Foulds, K. E., Zenewicz, L. A., Shedlock, D. J., Jiang, J., Troy, A. E. and Shen, H., Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses. J. Immunol. 2002. 168: 1528-1532.
46. Baru, A. M., Hartl, A., Lahl, K., Krishnaswamy, J. K., Fehrenbach, H., Yildirim, A. O., Garn, H. et al., Selective depletion of Foxp3+ Treg during sensitization phase aggravates experimental allergic airway inflammation. Eur. J. Immunol. 2010. 40: 2259-2266.